Pretreatment with Recombinant Flt3 Ligand Partially Protects against Progressive Cutaneous Leishmaniasis in Susceptible BALB/c Mice
Open Access
- 1 February 2001
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 69 (2) , 673-680
- https://doi.org/10.1128/iai.69.2.673-680.2001
Abstract
Dendritic cells are potent antigen-presenting cells that also produce interleukin-12 (IL-12) during innate and adaptive cellular immune responses and that thereby promote the differentiation of gamma interferon (IFN-γ)-producing Th1-type CD4+T lymphocytes. We hypothesized that expanded dendritic-cell populations in mice pretreated with the hematopoietic cytokine Flt3L would protect against cutaneousLeishmania majorinfection. Pretreatment of disease-susceptible BALB/c mice with 10 μg of recombinant Flt3L (rFlt3L) for 9 to 10 days before infection increased lymph node IL-12 p40 productive capacity 20-fold compared to that of saline-injected controls. Furthermore, 9 of 22 (40.9%) rFlt3L-pretreated BALB/c mice resolved their cutaneous infections, whereas none of the 22 control BALB/c mice healed. Healed, rFlt3L-pretreated mice did not develop disease following reinfection. Flt3L pretreatment also reduced parasite numbers 1,000-fold in the cutaneous lesions at 2 weeks after infection relative to numbers in lesions of untreated controls. However, Flt3L pretreatment did not significantly alterL. major-induced IFN-γ and IL-4 production in lymph node culture at 1, 2, and 4 weeks after infection. Despite the lack of Th immune deviation, Flt3L ligand-pretreated lymph nodes expressed up to 10-fold higher levels of IL-12 p40 and inducible (type 2) nitric oxide synthase mRNA at 7 days after infection. In contrast, treatment with rFlt3L after infection failed to protect against disease despite comparable expansions of dendritic cells and IL-12 p40 productive capacity in both infected and uninfected BALB/c mice treated with rFlt3L. We conclude that rFlt3L pretreatment before infection withL. majorreduces parasite load and promotes healing of cutaneous lesions without stable cytokine deviation towards a dominant Th1 cytokine phenotype.Keywords
This publication has 37 references indexed in Scilit:
- Underproduction of Interleukin-12 in Susceptible Mice during Progressive Leishmaniasis Is Due to Decreased CD40 ActivityCellular Immunology, 1998
- FLT3 Ligand Induces the Generation of Functionally Active Dendritic Cells in MiceCellular Immunology, 1997
- Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.The Journal of Experimental Medicine, 1996
- Protective Role of CD40 in Leishmania major Infection at Two Distinct Phases of Cell-Mediated ImmunityPublished by Elsevier ,1996
- Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice.The Journal of Experimental Medicine, 1996
- The Regulation of Immunity to Leishmania MajorAnnual Review of Immunology, 1995
- Antigen presentation by Leishmania mexicana‐infected macrophages: Activation of helper T cells specific for amastigote cysteine proteinases requires intracellular killing of the parasitesEuropean Journal of Immunology, 1995
- Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection.The Journal of Experimental Medicine, 1994
- Recombinant interleukin 12 cures mice infected with Leishmania major.The Journal of Experimental Medicine, 1993
- Establishment of Stable, Cell-Mediated Immunity that Makes "Susceptible" Mice Resistant to Leishmania majorScience, 1992